S. Lameire

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

B. Lambrecht, S. Marqusee, N. Callewaert, 2023, bioRxiv.

A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19

S. Tavernier, M. Guilliams, P. Stordeur, 2023, Science Translational Medicine.

Lung epithelial cells: upstream targets in type 2-high asthma.

H. Hammad, S. Lameire, 2023, European Journal of Immunology.

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

M. Moutschen, S. Tavernier, K. Vanhove, 2022, Respiratory Research.